Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
NPBthis companyNorthpointe Bancshares, Inc.	$15.92	7.84×	0.99×	1.19×	14.11×	-69.8%	50.9%	23.4%	17.7%	14.7%	3.9%	7.3%	2.7×	9.17×	0.48×	0.1×	2.0%	3	0.31	3	B+
ALXOALX Oncology Holdings Inc.	$1.23	-0.59×	2.33×	0×	-0.5×	-90.6%	0.0%	0.0%	0.0%	-391.4%	-262.0%	-139.1%	0.2×	0.11×	-64.93×	2.07×	0.0%	2	-2.66	2	C
CCCCC4 Therapeutics, Inc.	$3.19	-1.5×	0.62×	4.4×	-1.4×	-187.2%	77.8%	-290.7%	-292.1%	-40.9%	-31.4%	-62.7%	0.23×	0.14×	0×	7.81×	0.0%	3	-1.03	2	C
CGEMCullinan Therapeutics, Inc.	$11.71	-2.78×	1.5×	0×	-2.39×	-90.4%	0.0%	0.0%	0.0%	-53.8%	-58.7%	-28.8%	0.01×	0.39×	0×	10.25×	0.0%	1	9.54	2	C
ERASErasca, Inc.	$15.04	-8.45×	3.24×	0×	-8.47×	-99.3%	0.0%	0.0%	0.0%	-38.3%	-35.3%	-9.1%	0.14×	0.22×	0×	10.04×	0.0%	1	35.36	1	C-
LEGNLegend Biotech Corporation	$24.18	-13.59×	4×	3.89×	-15.15×	-9886.0%	60.3%	-13.3%	-28.8%	-29.6%	-9.6%	-4.2%	0.41×	2.1×	-6.38×	1.96×	0.0%	3	4.12	1	C-
Peer median	—	-2.78×	2.33×	0×	-2.39×	-99.3%	0.0%	0.0%	0.0%	-40.9%	-35.3%	-28.8%	0.2×	0.22×	0×	7.81×	0.0%	2	4.12	2	—